German firm RESprotect granted RedHill Biopharma an option to acquire exclusive global rights to its experimental cancer drug cancer RP101 and next-generation compounds for all indications, except for pancreatic cancer in South Korea. RP101 holds orphan drug status in both the U.S. and Europe as an adjunct treatment for pancreatic cancer.

Related Summaries